Article
Ibrutinib continues to wow in CLL/SLL
SAN DIEGO – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study...
News
Gastric cancer yields to growth hormone antagonist in lab
It sounds counterintuitive, but targeting a neuropeptide hormone produced in the hypothalamus may be an effective strategy for treating gastric...
Article
Diagnostic laparoscopy identifies ovarian cancers amenable to PCS
For women with suspected advanced epithelial ovarian cancer, diagnostic laparoscopy can help to distinguish between patients who could benefit...
Article
In NSCLC, delayed chemo yields survival benefit comparable to early chemo
In patients with non–small-cell lung cancer for whom adjuvant chemotherapy must be delayed for as long as 18 weeks, mortality outcomes are no...
Video
VIDEO: Watson helps oncologists sleuth out best options in breast cancer
SAN ANTONIO – Every day, practicing oncologists sort through mountains of data to make the best possible therapeutic decisions for their patients...
Article
PIK3 inhibitor gives slight PFS edge at high cost for HR+/HER2– advanced breast cancer
SAN ANTONIO – A combination of a PI3K inhibitor and selective estrogen receptor down-regulator (SERD) met its primary endpoint of 2.1 months...
Article
Novel trial aims to BEAT AML
SAN DIEGO - A multi-arm clinical trial aims to transform the treatment of acute myeloid leukemia, a deadly blood cancer whose standard of care has...
Article
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
SAN DIEGO – Lenalidomide, a mainstay of maintenance therapy for multiple myeloma, is now making inroads into maintenance therapy following first-...
Article
VIDEO: AIs associated with endothelial dysfunction, a predictor of CVD
SAN ANTONIO – Aromatase inhibitors (AIs) appear to be associated with declines in vascular endothelial function, which in turn have been...
Article
It’s elementary: Watson aids in breast cancer decisions
SAN ANTONIO – In this case, Watson is an artificial intelligence platform being developed in the United States and used in clinical practice in...
Article
VIDEO: Watson for Oncology offers electronic curbside consults in breast cancer
Andrew Norden, MD, describes how Watson for Oncology works, and how different versions of the Watson platform are being used in medicine...
Article
Aromatase inhibitor effect on endothelial function may lead to CVD
Aromatase inhibitors appear to have a decremental effect on vascular endothelial function, which could contribute to cardiovascular disease.
Article
No boost in pCR from neoadjuvant estrogen deprivation
Estrogen deprivation added to chemotherapy and dual HER2 inhibition did not improve pathologic complete responses, compared with chemotherapy...
Article
VIDEO: No improvement in pCR with dual ER and HER2 inhibition
SAN ANTONIO
Article
Optimal duration of extended AI therapy? Flip a coin
SAN ANTONIO – The optimal duration of aromatase inhibitor therapy following 5 years of endocrine therapy in postmenopausal women is still unknown...